The shares of the prominent drug manufacturer fell up to 2 percent in today’s trading session after the company received a warning letter from SEBI for a violation of insider trading regulations.
With a market capitalization of Rs 15,963.14 crore, the shares of Neuland Laboratories Ltd were trading at Rs 12,442.15 per share, increasing around 0.78 percent as compared to the previous closing price of Rs 12,540.05 apiece.
The shares of Neuland Laboratories Ltd have seen negative movement after receiving an administrative warning letter from SEBI for a violation of insider trading regulations by a designated person of the company. The company clarified that there is no material impact on its financials, operations, or other activities.
Looking forward to the company’s financial performance, revenue decreased by 15 percent from Rs 385 crore in Q4FY24 to Rs 328 crore in Q4FY25. Further, during the same time frame, net profit decreased by 59 percent from Rs 68 crore to Rs 28 crore.
Also read: Tata Group stock to buy now for an upside of 35%; Recommended by Morgan Stanley and Citi
As of March 2025, a prominent investor, Mukul Mahavir, holds 4,00,000 equity shares, which is equivalent to 3.12 percent in the company. With over 40 years of experience, the company has filed 980+ DMFs globally. It offers 100+ APIs across 10 therapeutic areas, with 82% revenue from exports. It holds 72 active US DMFs, has 1174 KL manufacturing capacity, and employs 1,794 people, highlighting strong global presence and capabilities.
The company has a strong global footprint, generating 86% of its revenue from Europe and North America. It’s headquartered in Hyderabad with three manufacturing units. Serving over 80 countries, it maintains a solid presence across APAC, MENA, LATAM, and India.
Neuland Laboratories Limited is an India-based company that is engaged in the manufacturing and selling of bulk drugs. The Company caters to both domestic and international markets. It manufactures active pharmaceutical ingredients (APIs) and is an end-to-end solution provider for the pharmaceutical industry’s chemistry needs.
Written by Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
